Jürgen C Dinger

Summary

Affiliation: Center for Epidemiology and Health Research Berlin
Country: Germany

Publications

  1. ncbi The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
    Jürgen C Dinger
    Center for Epidemiology and Health Research ZEG, 10115 Berlin, Germany
    Contraception 75:344-54. 2007
  2. ncbi International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study)
    Juergen C Dinger
    ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    BMC Med Res Methodol 9:77. 2009
  3. ncbi Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
    Jürgen Dinger
    Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    J Fam Plann Reprod Health Care 36:123-9. 2010
  4. ncbi Sensitivity as outcome measure of androgen replacement: the AMS scale
    Lothar A Heinemann
    Center for Epidemiology and Health Research Berlin, Invalidenstr 115, 10115 Berlin, Germany
    Health Qual Life Outcomes 4:23. 2006
  5. ncbi Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer
    Jürgen Dinger
    ZEG Berlin Center for Epidemiology and Health Research, Germany
    Contraception 83:211-7. 2011
  6. ncbi Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen
    Jürgen Dinger
    ZEG, Berlin Center for Epidemiology and Health Research, Berlin, Germany
    Obstet Gynecol 117:33-40. 2011
  7. ncbi Oral contraceptive effectiveness according to body mass index, weight, age, and other factors
    Jürgen C Dinger
    ZEG Center for Epidemiology and Health Research, Berlin, Germany
    Am J Obstet Gynecol 201:263.e1-9. 2009
  8. ncbi Colon cancer risk and different HRT formulations: a case-control study
    Jürgen C Dinger
    Centre for Epidemiology and Health Research Berlin, Berlin, Germany
    BMC Cancer 7:76. 2007
  9. ncbi Quality of life and hormone use: new validation results of MRS scale
    Jürgen Dinger
    Center for Epidemiology and Health Research Berlin, Invalidenstr, 115, 10115 Berlin, Germany
    Health Qual Life Outcomes 4:32. 2006
  10. ncbi Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare"
    Lothar A J Heinemann
    Berlin Center for Epidemiology and Health Research, Berlin, Germany
    Contraception 81:401-7. 2010

Detail Information

Publications13

  1. ncbi The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
    Jürgen C Dinger
    Center for Epidemiology and Health Research ZEG, 10115 Berlin, Germany
    Contraception 75:344-54. 2007
    ..The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs...
  2. ncbi International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study)
    Juergen C Dinger
    ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    BMC Med Res Methodol 9:77. 2009
    ....
  3. ncbi Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
    Jürgen Dinger
    Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    J Fam Plann Reprod Health Care 36:123-9. 2010
    ..The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE...
  4. ncbi Sensitivity as outcome measure of androgen replacement: the AMS scale
    Lothar A Heinemann
    Center for Epidemiology and Health Research Berlin, Invalidenstr 115, 10115 Berlin, Germany
    Health Qual Life Outcomes 4:23. 2006
    ..The capacity of the AMS scale as clinical utility and as outcome measure still needs validation...
  5. ncbi Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer
    Jürgen Dinger
    ZEG Berlin Center for Epidemiology and Health Research, Germany
    Contraception 83:211-7. 2011
    ..This study compares the risk of breast cancer for levonorgestrel-releasing intrauterine devices (LNG(IUD)) versus copper IUDs (CU(IUD)) in women younger than 50 years of age...
  6. ncbi Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen
    Jürgen Dinger
    ZEG, Berlin Center for Epidemiology and Health Research, Berlin, Germany
    Obstet Gynecol 117:33-40. 2011
    ....
  7. ncbi Oral contraceptive effectiveness according to body mass index, weight, age, and other factors
    Jürgen C Dinger
    ZEG Center for Epidemiology and Health Research, Berlin, Germany
    Am J Obstet Gynecol 201:263.e1-9. 2009
    ..The purpose of this study was to assess the use-effectiveness of oral contraceptives (OCs) in Europe according to body mass index (BMI), weight, age, and other factors...
  8. ncbi Colon cancer risk and different HRT formulations: a case-control study
    Jürgen C Dinger
    Centre for Epidemiology and Health Research Berlin, Berlin, Germany
    BMC Cancer 7:76. 2007
    ..Most studies have found no increased risk of colon cancer associated with hormone replacement therapy (HRT), or even a decreased risk. But information about the effects of different HRT preparations is lacking...
  9. ncbi Quality of life and hormone use: new validation results of MRS scale
    Jürgen Dinger
    Center for Epidemiology and Health Research Berlin, Invalidenstr, 115, 10115 Berlin, Germany
    Health Qual Life Outcomes 4:32. 2006
    ..The suspicion however was expressed that the data were too optimistic due to methodological problems of the study. A new study became available to check how founded this suspicion was...
  10. ncbi Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare"
    Lothar A J Heinemann
    Berlin Center for Epidemiology and Health Research, Berlin, Germany
    Contraception 81:401-7. 2010
    ..e., those containing desogestrel and gestodene) in the 1990s, which likely contributed to the alleged increased risk of VTE, may have vanished after 10 years...
  11. ncbi Safety of a new oral contraceptive containing drospirenone
    Lothar A J Heinemann
    Center for Epidemiology and Health Research, Berlin, Germany
    Drug Saf 27:1001-18. 2004
    ..Overall, the safety data with EE/DRSP and other OCs indicate that these products have no negative impact on the risk of VTE (and other adverse events) in women who receive OCs for contraception...
  12. ncbi Range of published estimates of venous thromboembolism incidence in young women
    Lothar A J Heinemann
    Center for Epidemiology and Health Research Berlin, 10115 Berlin, Germany
    Contraception 75:328-36. 2007
    ..This review was conducted to show the full range of incidence estimates published for venous thromboembolism (VTE) in women depending on study design and to suggest a more reliable estimate for women of reproductive age...
  13. ncbi Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives
    Maureen Cronin
    Bayer Schering Pharma AG, Mullerstrasse 178, Berlin, Germany
    Obstet Gynecol 114:616-22. 2009
    ..To determine whether prior oral-contraceptive use has a negative effect on the ability of women to conceive in both the short-term and long-term...